CooperDS. 2005. Antithyroid drugs. N Engl J Med, 352:905–917.
2.
ChoBY, ShongMH, YiKH, LeeHK, KohCS, MinHK. 1992. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. Clin Endocrinol (Oxf ), 36:585–590.
3.
Feldt-RasmussenU, SchleusenerH, CarayonP. 1994. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab, 78:98–102.
4.
SchottM, MorgenthalerNG, FritzenR, FeldkampJ, WillenbergHS, ScherbaumWA, SeisslerJ. 2004. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res, 36:92–96.
5.
ChungHK, ChooYK, YooWS, KimDW. 2010. Hypothyroidism during antithyroid drug treatment is a favorable prognostic indicator in patients with Graves' disease. Thyroid, 20:949–954.
6.
TorringO, TallstedtL, WallinG, LundellG, LjunggrenJG, TaubeA, SaafM, HambergerB. 1996. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab, 81:2986–2993.
7.
BrentGA. 2008. Clinical practice Graves' disease. N Engl J Med, 358:2594–2605.
TajiriJ, NoguchiS, MurakamiT, MurakamiN. 1990. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med, 150:621–624.
10.
PearceSH. 2004. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf ), 61:589–594.
11.
TakataK, KubotaS, FukataS, KudoT, NishiharaE, ItoM, AminoN, MiyauchiA. 2009. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid, 19:559–563.
12.
KimHJ, KimBH, HanYS, YangI, KimKJ, DongSH, KimHJ, ChangYW, LeeJI, ChangR. 2001. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol, 96:165–169.
BahnRS, BurchHS, CooperDS, GarberJR, GreenleeCM, KleinIL, LaurbergP, McDougallIR, RivkeesSA, RossD, SosaJA, StanMN. 2009. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid, 19:673–674.
15.
WeetmanAP. 2000. Graves' disease. N Engl J Med, 343:1236–1248.
16.
McGregorAM, PetersenMM, McLachlanSM, RookeP, SmithBR, HallR. 1980. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med, 303:302–307.
17.
SonnetE, MassartC, GibassierJ, AllannicH, MaugendreD. 1999. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest, 22:430–435.
18.
SalviM, GirasoleG, PedrazzoniM, PasseriM, GiulianiN, MinelliR, BravermanLE, RotiE. 1996. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab, 81:2976–2979.
19.
TsatsoulisA, VlachoyiannopoulosPG, DalekosGN, JohnsonEO, MoutsopoulosHM. 1995. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest, 25:654–658.
20.
MitsiadesN, PoulakiV, Tseleni-BalafoutaS, ChrousosGP, KoutrasDA. 2000. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid, 10:527–532.
21.
Zantut-WittmannDE, TambasciaMA, da Silva TrevisanMA, PintoGA, VassalloJ. 2001. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease. Thyroid, 11:575–580.
22.
TottermanTH, KarlssonFA, BengtssonM, Mendel-HartvigI. 1987. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med, 316:15–22.
23.
LaurbergP. 2006. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?Eur J Endocrinol, 155:783–786.
24.
WenzelKW, LenteJR. 1984. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab, 58:62–69.
25.
RomaldiniJH, BrombergN, WernerRS, TanakaLM, RodriguesHF, WernerMC, FarahCS, ReisLC. 1983. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab, 57:563–570.
26.
AbrahamP, AvenellA, ParkCM, WatsonWA, BevanJS. 2005. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol, 153:489–498.
27.
AbalovichM, AminoN, BarbourLA, CobinRH, De GrootLJ, MandelSJ, Stagnaro-GreenA. 2007. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 92:S1–47.
28.
ChattawayJM, KlepserTB. 2007. Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. Ann Pharmacother, 41:1018–1022.
29.
KaguelidouF, CarelJC, LegerJ. 2009. Graves' disease in childhood: advances in management with antithyroid drug therapy. Horm Res, 71:310–317.
30.
MetsoS, JaatinenP, HuhtalaH, AuvinenA, OksalaH, SalmiJ. 2007. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab, 92:2190–2196.
31.
ReadCHJr, TanseyMJ, MendaY. 2004. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab, 89:4229–4233.
32.
BartalenaL, MarcocciC, BogazziF, ManettiL, TandaML, Dell'UntoE, Bruno-BossioG, NardiM, BartolomeiMP, LepriA, RossiG, MartinoE, PincheraA. 1998. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med, 338:73–78.
33.
AcharyaSH, AvenellA, PhilipS, BurrJ, BevanJS, AbrahamP. 2008. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf ), 69:943–950.
